| Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). | |
| Price, Timothy Jay; Newhall, Kathryn; Peeters, Marc; Kim, Tae Won; Li, Jin; Cascinu, Stefano; Ruff, Paul; Suresh, Attili Venkatasatya; Thomas, Anne; Tjulandin, Sergei | |
| 2015 | |
| 卷号 | 33 |
| 期号 | 3 |
| 会议录 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 语种 | 英语 |
| URL标识 | 查看原文 |
| ISSN号 | 0732-183X |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4642430 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Price, Timothy Jay,Newhall, Kathryn,Peeters, Marc,et al. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).[C]. 见:. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论